Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

Executive Summary

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

Advertisement

Related Content

Bio-Techne Makes Big Push Into Liquid Biopsy With Exosome Acquisition
Inivata Launches Search For New CEO
ANGLE Reels In First Patient For Major US FDA Clinical Study
Angle's Maiden M&A Fills Gaps In Liquid Biopsy Solution
Market Intel: Can New Wave Of Tests Finally Nail Early Diagnosis Of Lung Cancer?
CLINICAL CORNER: Spectranetics’ DCB, Pixium’s Bionic Vision, Endologix EVAS, Biocartis’ Liquid Biopsy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT123118

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel